Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 Patients

Kim, Mi Ri; Kim, Hyeon Chang; Kim, Soo Chan

doi:10.1159/000332848

Cited by 26 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noted that we did not include the PV patients treated with rituximab (which may be a susceptibility factor for infection). Kim et al found that there was no difference in prednisolone alone or prednisolone plus adjuvant with regard to prognosis and time to remission in PV patients [19]. …”

Section: Discussionmentioning

confidence: 99%

Pemphigus Vulgaris and Infections: A Retrospective Study on 155 Patients

Esmaili

Mortazavi

Noormohammadpour

et al. 2013

Autoimmune Diseases

View full text Add to dashboard Cite

Background. Autoimmune process and immunosuppressive therapy of pemphigus vulgaris would predispose the patients to infections. Aim. We aimed to study the prevalence of infection and pathogenic agents in pemphigus vulgaris patients admitted to dermatology service. Material and methods. This retrospective study was conducted on 155 pemphigus vulgaris patients (68 males, 87 females) admitted to dermatology service between 2009 and 2011. In this study, the diagnosis of pemphigus vulgaris was confirmed by light microscopic and direct immunofluorescence findings. Data were collected through a questionnaire. Results. Of 155 pemphigus vulgaris patients, 33 had infection at admission and 9 acquired nosocomial infection. In addition, 37 cases of oral candidiasis and 15 cases of localized herpes simplex were recorded. Totally, 94 cases of infection were recorded. The occurrence of infection was significantly related to the severity of disease, number of hospital admissions, and presence of diabetes mellitus. The most common pathogenic germs isolated from cultures were Staphylococcus aureus and Escherichia coli. Conclusion. Severity of pemphigus vulgaris and diabetes were directly related with tendency to infections. Staphylococcus aureus and Escherichia coli were the most common pathogenic agents. Due to limitations of retrospective study, a prospective study is recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Pemphigus Vulgaris and Infections: A Retrospective Study on 155 Patients

Esmaili

Mortazavi

Noormohammadpour

et al. 2013

Autoimmune Diseases

View full text Add to dashboard Cite

show abstract

“…Thus, the study suggests rituximab to be an effective and safe drug for patients who are resistant to conventional therapy. [43]…”

Section: Autoimmune Vesiculobullous Disordersmentioning

confidence: 99%

Novel applications of Rituximab in dermatological disorders

Bhandari

Pai

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

Rituximab is a monoclonal therapeutic anti-CD20 antibody that has been approved for use in lymphoma and rheumatoid arthritis. Over the past decade several reports based on case series and observational studies have recorded the benefits of rituximab in particular groups of dermatological patients. Off-label use of rituximab in many dermatological indications is not uncommon in many countries in the world. This article reviews the available data that may be of use to the practicing dermatologist. Because of its potential complications, paucity of clinical data, and cost considerations, rituximab is favoured only when standard systemic therapies fail or corticosteroids are absolutely contraindicated. Further research is required in this field.

show abstract

“…Combination with other immunosuppressants, such as azathioprine, methotrexate, mycophenolate mofetil, cyclophosphamide and cyclosporine, allows for a steroid-sparing effect. Other treatment options include intravenous immunoglobulin, plasmapheresis, photopheresis, extracorporeal immunoabsorption, gold salts and dapsone [4,5,6]. Nevertheless, many patients never obtain remission, and others remain poorly controlled.…”

Section: Introductionmentioning

confidence: 99%

Pilot Study of 19 Patients with Severe Pemphigus: Prophylactic Treatment with Rituximab Does Not Appear to be Beneficial

Gregoriou

Giatrakou²,

Θεοδωρόπουλος³

et al. 2014

Dermatology

View full text Add to dashboard Cite

Aims: To assess the efficacy and safety of rituximab in refractory pemphigus and the possible benefit of an additional prophylactic infusion at 6 months. Methods: Seventeen patients with pemphigus vulgaris, 1 with pemphigus foliaceus and 1 with pemphigus vegetans were treated with 4 weekly infusions of rituximab (375 mg/m²). Nine patients received an additional prophylactic infusion after 6 months while the rest received no maintenance therapy. In case of recurrence, an additional single infusion was administered. Results: Control of the disease was obtained after 3-8 weeks. End of the consolidation phase for all patients was observed after 16 weeks. Patients remained in full remission for 7-42 months. All immunosuppressive agents, including prednisone, were discontinued after 2-12 months. The disease relapsed in 5 out of 9 patients who received the additional prophylactic infusion, and in 3 out of 10 patients among those skipping the prophylactic additional infusion. Conclusion: One course of rituximab and treatment of relapses is highly effective and well tolerated in the treatment of refractory pemphigus. In this pilot study of 19 patients, the prophylactic infusion does not appear to have provided any additional benefit to the patients receiving it.

show abstract

Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 Patients

Cited by 26 publications

References 36 publications

Pemphigus Vulgaris and Infections: A Retrospective Study on 155 Patients

Pemphigus Vulgaris and Infections: A Retrospective Study on 155 Patients

Novel applications of Rituximab in dermatological disorders

Pilot Study of 19 Patients with Severe Pemphigus: Prophylactic Treatment with Rituximab Does Not Appear to be Beneficial

Contact Info

Product

Resources

About